OptiNose Inc

NASDAQ:OPTN   3:46:53 PM EDT
1.73
-0.15 (-7.98%)
Other Pre-Announcement

Optinose Reports Q3 2022 Financial Results

Published: 11/10/2022 12:47 GMT
OptiNose Inc (OPTN) - Optinose Reports Third Quarter 2022 Financial Results and Operational Updates.company Plans to Submit an Snda for Xhance As a Treatment for Chronic Sinusitis in Early 2023.
Expects Full Year 2022 Xhance Net Revenue to Be Between $74 to $78 Million.
Cash and Cash Equivalents of $61.1 Million As of September 30, 2022.
Qtrly Loss per Share $0.18.
Q3 Earnings per Share View $-0.19 -- Refinitiv Ibes Data (analyst estimates).